[PRNewswire] Trisol announces successful implants in the US
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
The second case was performed in a 77-year-old woman with severe symptomatic TR at the University of Virginia Health System. The TR level was reduced from severe to trace, and the patient was discharged from the hospital within two days after the procedure. According to Scott Lim, MD of University of Virginia Health System who conducted the second case "The patient had a gratifying result with essentially elimination of her tricuspid regurgitation, and rapid recovery, along with significant and rapid improvement in her symptoms. We look forward to further investigation of the Trisol valve".
이 보도자료는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았으며, 연합뉴스의 편집방향과는 무관함을 밝혀 드립니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
-- Trisol's first two implants of Transcatheter Tricuspid Valve
-- Two implants were successfully conducted as part of the FDA approved Early Feasibility Study in the United States
YOKNEAM, Israel Aug 23, 2023 /PRNewswire=연합뉴스/ -- The heart teams at the Piedmont Heart Institute in Atlanta, Georgia, USA and the University of Virginia Health System in Charlottesville, VA, USA, successfully performed the first two implantations in the US of the Trisol[https://trisol-medical.com/ ] Transcatheter Tricuspid Valve Replacement as part of a U.S. Food and Drug Administration approved Early Feasibility Study (EFS), led by Principal Investigator Isaac George, MD.
The first case was performed in an 84-year-old woman with severe symptomatic tricuspid regurgitation (TR) at Piedmont Heart Institute through the right internal jugular vein. The TR level was reduced from severe to none and the patient was discharged from the hospital within two days after the procedure. According to Pradeep Yadav, MD, James Stewart, MD, and Vinod Thourani, MD of the Piedmont Heart Institute who conducted the first case "This marks a major milestone in the management of TR. We were able to abolish the patient's valvular heart disease via a minimally invasive procedure without the need for cardiopulmonary bypass. The patient was mobilizing within hours of the procedure and her recovery was steam-lined and expeditious".
The second case was performed in a 77-year-old woman with severe symptomatic TR at the University of Virginia Health System. The TR level was reduced from severe to trace, and the patient was discharged from the hospital within two days after the procedure. According to Scott Lim, MD of University of Virginia Health System who conducted the second case "The patient had a gratifying result with essentially elimination of her tricuspid regurgitation, and rapid recovery, along with significant and rapid improvement in her symptoms. We look forward to further investigation of the Trisol valve".
"We are fortunate to collaborate with such skilled investigators. We are pleased with the preliminary outcomes and look forward to ongoing progress of the U.S. EFS", says Ron Davidson, Trisol's CEO. Dr. Shimon Eckhouse, Trisol's Chairman, further remarked: "There is a huge unmet need for a transcatheter solution to treat severe TR. Trisol's promising initial clinical data instills confidence that Trisol can play a major role in this domain".
Trisol patented valve features a distinctive design, that sets it apart from other tricuspid valves technologies. Trisol valve is comprised of a single leaflet, the leaflet is affixed by 2 commissures enabling it to function as a bi-leaflet valve. Notably, this novel design facilitates a slower closing of the leaflets, a feature intended to preserve the right ventricular function following the valve replacement. Trisol's valve employs axial anchoring, that reduces the risk of conductive issues.
To date, Trisol Valve has been implanted in ten human subjects. Five of these implants were performed as part of the Israeli Pilot Study, led by Principal Investigator Ran Kornowski, MD. Currently, the longest follow-up period exceeds 2 years. Trisol aims to complete its EFS and initiate pivotal studies in 2024.
About Trisol
Trisol[https://trisol-medical.com/ ] Medical Ltd. is a clinical-stage medical device company focused on the development of a Transcatheter Tricuspid Valve Replacement. Trisol was founded by Mordehay Vaturi, MD, a senior Cardiologist at Rabin Medical Centre, Ron Davidson, a seasoned Medtech executive, and Eli Ben-Hamou, an expert in structural heart engineering. The company was incepted in 2016 within the Alon MedTech Ventures incubator, owned by Dr. Shimon Eckhouse, a prominent Medtech entrepreneur and investor. For further details, please visit: www.trisol-medical.com
Media Contact:
Ron Davidson
CEO
Email: rond@trisol-medical.com
Photo - https://mma.prnewswire.com/media/2192351/Trisol_valve.jpg
An illustration depicting Trisol valve deployment.
Source: Trisol Medical
[편집자 주] 이 보도자료는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았으며, 연합뉴스의 편집방향과는 무관함을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.
- 4분기 전기요금 일단 동결…연료비조정단가 '+5원' 유지 | 연합뉴스
- 이스라엘·헤즈볼라 가자전쟁 이후 최대 교전…전면전 초읽기(종합2보) | 연합뉴스
- "삼성·TSMC, 중동에 반도체공장 설립 추진…양사, UAE와 논의"(종합) | 연합뉴스
- 의정갈등 속 서울대·삼성서울병원 등 신규 간호사 채용 개시 | 연합뉴스
- 尹대통령 지지율 30.3%…4주 만에 30%대 회복[리얼미터] | 연합뉴스
- 빚 못갚는 소상공인 지속 증가…지역신보 대위변제 60%↑ | 연합뉴스
- 소녀상 훼손 방지 위한 정부 첫 실태조사, 시작부터 '허술' | 연합뉴스
- "해리스, 트럼프에 전국서는 4%p·경합주서는 2%p 각각 우위" | 연합뉴스
- 국회 여가위, 오늘 '딥페이크 성범죄 방지법' 의결 | 연합뉴스
- 10대 향정신성 의약품 사범 2년간 7배…"대책 마련 시급" | 연합뉴스